Erlotinib Terminated Phase 2 Trials for Ependymomas Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01247922Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205